The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines

Vaccine

Volumn 26, Issue 39, 2008, Pages 4998-5003

  Thompson, Joseph M ^a,b   Whitmore, Alan C ^b   Staats, Herman F ^c   Johnston, Robert ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant activity; Mucosal IgA; Type I IFN; Viral immunity

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OVALBUMIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; INFLUENZA VIRUS; INTERFERON PRODUCTION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SIGNAL TRANSDUCTION; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INTERFERON TYPE I; MICE; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; OVALBUMIN; REPLICON; VIRAL VACCINES;

EID: 50549095923     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.011     Document Type: Article

References (37)

1. Isaacs A., and Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147 927 (1957) 258-267
2. Sen G.C. Viruses and interferons. Annu Rev Microbiol 55 1 (2001) 255-281
3. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
4. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons {alpha} and {beta} and alters macrophage responses. PNAS 92 24 (1995) 11284-11288
5. van den Broek M.F., Muller U., Huang S., Zinkernagel R.M., and Aguet M. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148 (1995) 5-18
6. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 5167 (1994) 1918-1921
7. Durbin J.E., Fernandez-Sesma A., Lee C.K., Rao T.D., Frey A.B., Moran T.M., et al. Type I IFN modulates innate and specific antiviral immunity. J Immunol 164 8 (2000) 4220-4228
8. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons in immunity and autoimmunity. Annu Rev Immunol 23 1 (2005) 307-335
9. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-α\β), in innate and adaptive immune responses to viral infections. Semin Immunol 10 5 (1998) 383-390
10. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
11. Stetson D.B., and Medzhitov R. Type I interferons in host defense. Immunity 25 3 (2006) 373-381
12. Le Bon A., and Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14 4 (2002) 432-436
13. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 4 (2001) 461-470
14. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 9 (2002) 822-829
15. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176 4 (2006) 2074-2078
16. Havenar-Daughton C., Kolumam G.A., and Murali-Krishna K. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176 6 (2006) 3315-3319
17. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., and Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 5 (2005) 637-650
18. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., and Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17 1 (1999) 189-220
19. Strauss J.H., and Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58 3 (1994) 491-562
20. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., and Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239 2 (1997) 389-401
21. Harrington P.R., Yount B., Johnston R.E., Davis N., Moe C., and Baric R.S. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing norwalk virus-like particles. J Virol 76 2 (2002) 730-742
22. LoBue A.D., Lindesmith L., Yount B., Harrington P.R., Thompson J.M., Johnston R.E., et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24 24 (2006) 5220-5234
23. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M.B., Davis N.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. PNAS 103 10 (2006) 3722-3727
24. Thompson J.M., Nicholson M.G., Whitmore A.C., Zamora M., West A., Iwasaki A., et al. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol 181 1 (2008) 574-585
25. Thompson J.M., Whitmore A.C., Staats H.F., and Johnston R.E. Alphavirus replicon particles acting as adjuvants promote CD8(+) T cell responses to co-delivered antigen. Vaccine 26 33 (2008) 4267-4275
26. Alsharifi M., Lobigs M., Regner M., Lee E., Koskinen A., and Mullbacher A. Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J Immunol 175 7 (2005) 4635-4640
27. Leitner W.W., Bergmann-Leitner E.S., Hwang L.N., and Restifo N.P. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24 24 (2006) 5110-5118
28. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9 1 (2003) 33-39
29. Davis N.L., Caley I.J., Brown K.W., Betts M.R., Irlbeck D.M., McGrath K.M., et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 74 1 (2000) 371-378
30. Hidmark A.S., Nordstrom E.K.L., Dosenovic P., Forsell M.N.E., Liljestrom P., and Karlsson Hedestam G.B. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol 80 14 (2006) 7100-7110
31. Moran T.P., Collier M., McKinnon K.P., Davis N.L., Johnston R.E., and Serody J.S. A novel viral system for generating antigen-specific T cells. J Immunol 175 5 (2005) 3431-3438
32. MacDonald G.H., and Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74 2 (2000) 914-922
33. Huckriede A., Bungener L., Holtrop M., de Vries J., Waarts B.-L., Daemen T., et al. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22 9-10 (2004) 1104-1113
34. Bracci L., Canini I., Venditti M., Spada M., Puzelli S., Donatelli I., et al. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine 24 Suppl. 2 (2006) S2-56-7
35. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169 1 (2002) 375-383
36. Bracci L., Canini I., Puzelli S., Sestili P., Venditti M., Spada M., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 23 (2005) 2994-3004
37. Ryman K.D., White L.J., Johnston R.E., and Klimstra W.B. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol 15 1 (2002) 53-76